Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest announcement is out from Purple Biotech ( (PPBT) ).
Purple Biotech announced the advancement of NT219 into a Phase 2 study for the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) as of February 18, 2025. This study, conducted in collaboration with the University of Colorado Anschutz Medical Campus, aims to evaluate NT219 in combination with pembrolizumab or cetuximab to address tumor resistance in SCCHN. The Phase 2 trial’s design involves two single-arm cohorts, each assessing NT219’s efficacy with one of the two standard-of-care drugs. This progression underscores Purple Biotech’s commitment to addressing significant unmet medical needs in cancer treatment, potentially establishing a new standard of care.
More about Purple Biotech
Purple Biotech Ltd. (NASDAQ/TASE: PPBT) is a clinical-stage biotechnology company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance. The company’s oncology pipeline includes CM24, NT219, and CAPTN-3, targeting various mechanisms of tumor survival and immune interaction to improve treatment outcomes in aggressive cancers.
YTD Price Performance: -32.46%
Average Trading Volume: 977,381
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $8.78M
For detailed information about PPBT stock, go to TipRanks’ Stock Analysis page.
